Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland
ConclusionsOur results are in keeping with the phase III study findings: response rate, PFS and OS were similar to those reported in the phase III ANNOUNCE trial.
Source: Clinical Sarcoma Research - Category: Cancer & Oncology Source Type: research
More News: Anemia | Cancer & Oncology | Ireland Health | Leiomyosarcoma | Liposarcoma | Sarcomas | Soft Tissue Sarcoma | Study | Toxicology